38 terminated. 38 Phase 2, 3 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Terminated 38 |
| Phase 1 | 3 | Terminated 3 |
| Phase 3 | 3 | Terminated 3 |
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) zetomipzomib, placebo - Lupus Nephritis | Phase 2 | Terminated | Kezar Life Sciences, Inc. | 84 | 2023-11-03 | 2025-12-05 |
| Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy Peginterferon Alfa-2A 180 MCG/ML Injectable Solution - Membranous Nephropathy | Phase 2 | Terminated | Centre Hospitalier Universitaire de Nice | 4 | 2023-09-14 | 2026-06-18 |
| Efficacy and Safety of SHR-2010 Injection in the Treatment of Primary IgA Nephropathy SHR-2010 Injection, Placebo - Primary IgA Nephropathy | Phase 2 | Terminated | Guangdong Hengrui Pharmaceutical Co., Ltd | 53 | 2023-06-04 | 2025-03-05 |
| KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 6 | 2023-04-28 | 2026-08-31 |
| Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN) Daxdilimab, Placebo (Normal Saline) - Lupus Nephritis | Phase 2 | Terminated | Amgen | 19 | 2023-04-26 | 2025-03-24 |
| A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) efgartigimod IV, placebo - Membranous Nephropathy | Phase 2 | Terminated | argenx | 8 | 2023-02-20 | 2024-11-22 |
| KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen - Lupus Nephritis, Lupus Nephritis - WHO Class III | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 2 | 2022-12-01 | 2026-08-31 |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V Iptacopan (part 1), Iptacopan (part 2), Placebo + standard of care - Lupus Nephritis | Phase 2 | Terminated | Novartis Pharmaceuticals | 81 | 2022-08-10 | 2026-10-15 |
| Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) VB119 - Minimal Change Disease, Focal Segmental Glomerulosclerosis | Phase 2 | Terminated | Tenet Medicines | 1 | 2022-05-03 | 2024-04-22 |
| Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) AT-1501 - IgA Nephropathy, IgAN | Phase 2 | Terminated | Eledon Pharmaceuticals | 24 | 2022-03-21 | 2024-03-26 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) BCX9930 - Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy | Phase 2 | Terminated | BioCryst Pharmaceuticals | 2 | 2022-02-18 | 2024-05-02 |
| Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) ALXN2050, Placebo - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 100 | 2022-01-14 | 2025-10-15 |
| A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Telitacicept 160mg, Telitacicept 240mg, Placebo - IgA Nephropathy | Phase 2 | Terminated | RemeGen Co., Ltd. | 15 | 2021-11-04 | 2023-12-06 |
| An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases GFB-887 - Kidney Diseases, Glomerulosclerosis | Phase 2 | Terminated | Goldfinch Bio, Inc. | 31 | 2021-07-27 | 2022-11-15 |
| Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy VB119 - Membranous Nephropathy | Phase 1 / Phase 2 | Terminated | Tenet Medicines | 6 | 2021-05-05 | 2026-02-12 |
| Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo, Background Therapy - Lupus Nephritis, Immunoglobulin A Nephropathy | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 123 | 2021-01-19 | 2026-01-22 |
| A Study of Guselkumab in Participants With Active Lupus Nephritis Guselkumab Dose 1, Placebo, Guselkumab Dose 2 - Lupus Nephritis | Phase 2 | Terminated | Janssen Research & Development, LLC | 33 | 2020-09-15 | 2025-03-30 |
| A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease GFB-887, Placebo - Kidney Diseases, Diabetic Nephropathies | Phase 2 | Terminated | Goldfinch Bio, Inc. | 96 | 2020-07-28 | 2022-11-15 |
| Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy AVB-S6-500 - IgA Nephropathy | Phase 2 | Terminated | Aravive, Inc. | 1 | 2019-11-27 | 2022-02-10 |
| Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy LNP023, Rituximab - Idiopathic Membranous Nephropathy | Phase 2 | Terminated | Novartis Pharmaceuticals | 37 | 2019-11-23 | 2024-10-09 |
Showing 20 of 38. Sign in to see all of them.
Lupus Nephritis (15) · Glomerulonephritis, IGA (11) · Glomerulonephritis (8) · Proteinuria (7) · Glomerulonephritis, Membranous (6) · Kidney Diseases (6) · Glomerulosclerosis, Focal Segmental (5) · Lupus Erythematosus, Systemic (4) · Autoimmune Diseases (2) · Glomerulonephritis, Membranoproliferative (2) · Nephrosis (2) · Nephrosis, Lipoid (2) · Pyelonephritis (2) · Urologic Diseases (2)
Female Urogenital Diseases (38) · Female Urogenital Diseases and Pregnancy Complications (38) · Male Urogenital Diseases (38) · Urogenital Diseases (38) · Urologic Diseases (36) · Kidney Diseases (32) · Immune System Diseases (29) · Glomerulonephritis (27) · Autoimmune Diseases (26) · Skin and Connective Tissue Diseases (17) · Connective Tissue Diseases (16) · Lupus Erythematosus, Systemic (11) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7)
Mycophenolic Acid (4) · Adrenal Cortex Hormones (3) · BIIB023 (2) · Cyclophosphamide (2) · Rituximab (2) · TACI receptor-IgG Fc fragment fusion protein (2) · fludarabine (2) · 3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (1) · CCX140-B (1) · Cilastatin, Imipenem Drug Combination (1) · Etanercept (1) · Infliximab (1) · Interferon-alpha (1) · KZR-616 (1) · PF-06730512 (1)
Alexion Pharmaceuticals, Inc. (3) · Amgen (2) · Biogen (2) · Goldfinch Bio, Inc. (2) · Kyverna Therapeutics (2) · Novartis Pharmaceuticals (2) · Tenet Medicines (2) · Alnylam Pharmaceuticals (1) · Aravive, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Aurinia Pharmaceuticals Inc. (1) · BioCryst Pharmaceuticals (1) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Nice (1) · EMD Serono (1)
United States (27) · Spain (15) · France (11) · United Kingdom (11) · Germany (10) · China (9) · Argentina (8) · Australia (8) · Italy (8) · Malaysia (8) · Taiwan (8) · Mexico (7) · Philippines (7) · Poland (7) · Brazil (6)
Carla M Nester, MD, MSA, FASN (1) · David Elkharrat, MD (1) · David Wofsy, MD (1) · Falk Hiepe, MD (1) · Fernando C. Fervenza, M.D., Ph.D. (1) · Francoise Desir (1) · Hong Zhang, MD, PHD (1)
PMID 37528520, PMID 38299639, PMID 21325353, PMID 22325903, PMID 25348524, PMID 33159213, PMID 34169203, PMID 36423588, PMID 38724717, PMID 38829703, PMID 39455063, PMID 39673415, PMID 39899371
2018 (3), 2019 (3), 2016 (1), 2017 (1), UL1RR024150 (1)